Skip to main content

Volume 2 • Issue 1 • 2011

Review Article


Hormones and receptors in endometrial cancer

  • David Bender
  • Thomas Buekers
  • Kimberly Leslie

Volume 2 • Issue 1 • 2011 • 1–25

Wnt/ß-catenin/Lef-1 signaling in the uterus and its implications in uterine gland formation and cancer development

  • Dawne N. Shelton
  • Michael J. Goodheart

Volume 2 • Issue 1 • 2011 • 1–11

Article


Toward a microRNA signature of endometrial cancer

  • Eric J. Devor
  • Michael J. Goodheart
  • Kimberly K. Leslie

Volume 2 • Issue 1 • 2011 • 1–7

Case Report


Positron emission tomography in detection of metastatic leiomyosarcoma in a postoperative patient: a case report

  • David B Engle
  • Linda M. Smiley
  • Scott L. Baum
  • Greg P. Wellman

Volume 2 • Issue 1 • 2011 • 1–5

Diagnosis of endometrial cancer complicated by morbid obesity—a case report

  • Janna Girardi
  • Michael Goodheart

Volume 2 • Issue 1 • 2011 • 1–5

Board Member Spotlight


Michael J. Goodheart, MD

  • Kristina W. Thiel

Volume 2 • Issue 1 • 2011 • 1–2

Abstract


The relationship between vascularity, p53 gene mutations and distant metastatic disease in epithelial ovarian carcinoma

  • Janna Girardi
  • Megan Samuelson
  • Anna Button
  • Koen De Geest
  • David P. Bender
  • Amina Ahmed
  • Michael Goodheart

Volume 2 • Issue 1 • 2011 • 1–2

Lymphoid Enhancing Factor 1 (Lef-1) overexpression in epithelial ovarian, fallopian tube and peritoneal cancer and associations with clinical factors

  • Aine Clements
  • David Engle
  • Dawne Shelton
  • Traci Neff
  • Soo Park
  • David Bender
  • Amina Ahmed
  • Koen De Geest
  • Anna Button
  • John F. Engelhardt
  • Michael Goodheart

Volume 2 • Issue 1 • 2011 • 1–2

Combination therapy with mTOR and PI3 kinase inhibitors is broadly synergistic in a wide variety of endometrial cancer cells

  • Shujie Yang
  • Xue Xiao
  • Xiangbing Meng
  • Kimberly K. Leslie

Volume 2 • Issue 1 • 2011 • 1–2

Comparison of P53 mutation status, primary cytoreductive surgical outcomes, and overall survival in patients with ovarian cancer

  • David Engle
  • Hubert Fornalik
  • Traci Neff
  • Anna Button
  • K Collins
  • Amina Ahmed
  • David Bender
  • Susan Lutgendorf
  • Michael Goodheart

Volume 2 • Issue 1 • 2011 • 1–2

Zmiz1 is overexpressed in epithelial ovarian cancer and associated with p53 gene mutations

  • Niyati J Nadkarni
  • Laura M. Rogers
  • Megan Samuelson
  • Traci Neff
  • David P. Bender
  • Amina Ahmed
  • Koen De Geest
  • Anna Button
  • Adam Dupuy
  • Michael Goodheart

Volume 2 • Issue 1 • 2011 • 1–2

MiR-888: A newly identified miRNA significantly over-expressed in endometrial cancers

  • Adriann M. Hovey
  • Eric J. Devor
  • Kimberly K. Leslie

Volume 2 • Issue 1 • 2011 • 1–1

Knockdown of MTDH increases drug sensitivity to HDAC inhibitor and TRAIL combination treatment in endometrial cancer cells

  • Xiangbing Meng
  • Pavla Brachova
  • Shujie Yang
  • Zhi Xiong
  • Yuping Zhang
  • Kimberly K. Leslie

Volume 2 • Issue 1 • 2011 • 1–2

H19/miR-675 non-coding RNA expression differentiates among cancers of the human endometrium.

  • Eric J Devor
  • Jill N. DeMik
  • Brandon M. Schickling
  • Michael J. Goodheart
  • Kimberly K. Leslie

Volume 2 • Issue 1 • 2011 • 1–1

The combination of Paclitaxel and Gefitinib inhibits endometrial cancer cells by inducing mitotic catastrophe: proof of principle for dual therapy in endometrial cancer

  • Xiangbing Meng
  • Laura L. Laidler
  • Lina Albitar
  • Anna M. Holmes
  • Donghai Dai
  • Thomas E. Buekers
  • David P. Bender
  • Kimberly K. Leslie

Volume 2 • Issue 1 • 2011 • 1–2

Extended Abstract


Long-term Outcomes Among Women With Cervical Cancer Treated from 1960-1987

  • Christopher Yopp
  • Jo Benda
  • Colleen Stockdale
  • Jami L Shepard
  • Amina Ahmed

Volume 2 • Issue 1 • 2011 • 1–2